SOPHiA GENETICS Reports Strong Q3 Growth and Raises Guidance

Sophia Genetics Sa ( (SOPH) ) has released its Q3 earnings. Here is a breakdown of the information Sophia Genetics Sa presented to its investors.

SOPHiA GENETICS, a cloud-native healthcare technology company, leverages AI to enhance precision medicine, focusing on cancer and rare disorders. In its third quarter of 2025, SOPHiA GENETICS reported a revenue increase of 23% year-over-year, reaching $19.5 million, and adjusted gross margin remained strong at 73.1%. Despite a net IFRS loss of $20 million, the company showed a 13% improvement in adjusted EBITDA loss when excluding certain charges. Key highlights include the addition of 31 new customers and significant growth in the U.S. market, with a 30% revenue increase. The company’s strategic focus on expanding its SOPHiA DDM platform and partnerships with major institutions like AstraZeneca and Myriad Genetics are expected to drive future growth. Looking forward, SOPHiA GENETICS has raised its 2025 revenue guidance to $75-$77 million, anticipating continued momentum and approaching adjusted EBITDA breakeven by the end of 2026.